NASDAQ:OPGN OpGen (OPGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock About OpGen Stock (NASDAQ:OPGN) 30 days 90 days 365 days Advanced Chart Get OpGen alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$5.0252-Week Range N/AVolume143 shsAverage Volume8,849 shsMarket Capitalization$396 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. Read More Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address OPGN Stock News HeadlinesOpGen Forms Joint Venture with European BankMay 29, 2025 | tipranks.comOpGen Delays 10-Q Filing Amid Operational ChallengesMay 16, 2025 | tipranks.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.August 10 at 2:00 AM | Weiss Ratings (Ad)OpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital LtdDecember 11, 2024 | nl.investing.comOpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoenDecember 10, 2024 | nl.investing.comOpGen Appoints New COO and Company SecretaryDecember 6, 2024 | tipranks.comOpGen (OTC:OPGN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOPGN Stock Earnings: OpGen Reported Results for Q2 2024August 21, 2024 | investorplace.comSee More Headlines OPGN Stock Analysis - Frequently Asked Questions How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) announced its earnings results on Thursday, August, 10th. The medical research company reported ($9.30) EPS for the quarter, missing analysts' consensus estimates of ($7.10) by $2.20. The medical research company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.90 million. When did OpGen's stock split? Shares of OpGen reverse split on Monday, May 20th 2024.The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did OpGen IPO? OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager. How do I buy shares of OpGen? Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that OpGen investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Broadcom (AVGO). Company Calendar Last Earnings8/10/2023Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:OPGN CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.67 million Net Margins-1,140.36% Pretax Margin-742.42% Return on EquityN/A Return on Assets-287.58% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$2.67 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($11.55) per share Price / BookN/AMiscellaneous Outstanding Shares10,071,000Free Float4,696,000Market Cap$396 thousand OptionableNot Optionable Beta-1.66 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:OPGN) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.